文献速递复苏、休克与脓毒症呼吸衰竭与机械通气

心脏骤停中先给血管加压药还是先建立高级气道?

Vasopressor or advanced airway first in cardiac arrest?
PubMed 文献 · Resuscitation · 2024-10-30
一句话结论在PART试验中,血管加压药-高级气道复苏顺序与院外心脏骤停结局及心肺复苏质量无关。

该研究分析PART试验中2404例院外心脏骤停患者,根据首次给予血管加压药(肾上腺素或血管加压素)与成功置入高级气道(喉罩或气管插管)的先后顺序分为血管加压药优先组(1821例)和高级气道优先组(583例)。调整混杂因素后,血管加压药优先顺序与72小时生存、急诊科到达时自主循环恢复、出院生存及出院时神经功能良好生存均无显著关联,也与心肺复苏质量参数不达标无关。研究提示两者先后顺序对结局无显著影响。

要点

  • 在2404例院外心脏骤停患者中,血管加压药优先组1821例,高级气道优先组583例。
  • 血管加压药优先与72小时生存无关(调整OR 0.96;95%CI 0.71-1.31)。
  • 血管加压药优先与急诊科到达时自主循环恢复无关(调整OR 0.83;95%CI 0.66-1.06)。
  • 血管加压药优先与出院生存(调整OR 1.09;95%CI 0.68-1.73)及神经功能良好生存(调整OR 0.97;95%CI 0.53-1.78)无关。
  • 血管加压药优先顺序与心肺复苏质量参数不达标无关。

适用人群与场景

  • 院外心脏骤停患者,来自PART试验,共分析2404例,其中血管加压药优先组1821例,高级气道优先组583例。

处置流程与药物剂量

  • 首次给予血管加压药(肾上腺素或血管加压素)定义为血管加压药优先;成功置入高级气道(喉罩或气管插管)定义为高级气道优先。
  • 高级生命支持到达至血管加压药中位时间8分钟(IQR 6-11),至高级气道中位时间11分钟(IQR 8-15)。

研究设计与关键结果

  • 研究类型为对PART试验数据的二次分析,纳入2404例院外心脏骤停患者,比较血管加压药优先(1821例)与高级气道优先(583例)两种顺序。
  • 主要终点:血管加压药优先与高级气道优先相比,72小时生存调整OR 0.96(95%CI 0.71-1.31),无显著关联。
  • 次要终点:急诊科到达时自主循环恢复调整OR 0.83(95%CI 0.66-1.06),出院生存调整OR 1.09(95%CI 0.68-1.73),出院时神经功能良好生存调整OR 0.97(95%CI 0.53-1.78),均无显著关联。
  • 血管加压药优先顺序与心肺复苏质量参数不达标(胸外按压分数<0.8、按压频率<100或>120次/分、通气频率<8或>12次/分)无关。

证据类型、等级与局限

  • 证据类型:对PART试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,血管加压药-高级气道复苏顺序与院外心脏骤停结局或心肺复苏质量无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: While resuscitation guidelines emphasize early vasopressor administration and advanced airway management, their optimal sequence remains unclear. We sought to determine the associations between vasopressor-airway resuscitation sequence and out-of-hospital cardiac arrest (OHCA) outcomes in the Pragmatic Airway Resuscitation Trial (PART).

METHODS: We analyzed data from the PART trial. For each patient we determined times of first vasopressor administration (epinephrine or vasopressin), and successful advanced airway insertion (laryngeal tube or endotracheal tube). We classified each case as vasopressor-first or advanced airway-first. We used Generalized Estimating Equations to determine associations between vasopressor-airway sequence and outcomes (72-hour survival, return of spontaneous circulation (ROSC) on emergency department arrival, survival to hospital discharge, hospital survival with favorable neurologic status) and CPR outside of recommended parameters (chest compression fraction <0.8, chest compression rate <100 or >120 per min, or ventilation rate <8 or >12 breaths/min), adjusting for confounders.

RESULTS: Of 3,004 patients in the parent trial, we analyzed 2,404, including 1,821 vasopressor-first and 583 advanced airway-first. Median intervention times: ALS arrival-to-vasopressor 8 min (IQR 6-11) and ALS arrival-to-airway 11 min (8-15). Compared with airway-first, vasopressor-first sequence was not associated with 72-hour survival (adjusted OR 0.96; 95% CI: 0.71-1.31), ROSC (0.83; 0.66-1.06), hospital survival (1.09; 0.68-1.73), or hospital survival with favorable neurologic status (0.97; 0.53-1.78). Vasopressor-first sequence was not associated with non-compliance with recommended CPR performance parameters.

CONCLUSIONS: Vasopressor-airway resuscitation sequence was not associated with OHCA outcomes or CPR quality.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Wang HE, Daya MR, Schmicker R, et al. Vasopressor or advanced airway first in cardiac arrest? Resuscitation. 2024. PMID: 39486473. doi:10.1016/j.resuscitation.2024.110422

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。